Biomarkers in Renal Cancer

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2014 Feb 4

PMID 24487793

Citations 18

Authors

Holger Moch

John Srigley

Brett Delahunt

Rodolfo Montironi

Lars Egevad

Puay Hoon Tan

Affiliations

Soon will be listed here.

Abstract

Treatment options for primary and metastatic renal cancer are increasing. Accurate data from the pathological examination of renal cancer specimens aid clinicians in stratifying patients for surveillance and adjuvant therapies. This review focuses on biomarkers in diagnosis, prognosis and prediction of the biologic behavior of renal tumors which should be recorded in pathology reports and which are under investigation. Special emphasis is given to the use of immunohistochemical markers in differential diagnosis of various renal tumor subtypes. The relevance of cytogenetic and molecular findings is also discussed. The review includes the 2012 International Society for Urological Pathology Consensus conference recommendations.

Citing Articles

circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4.

Wang Y, Yang T, Li Q, Zheng Z, Liao L, Cen J Mol Cancer. 2025; 24(1):1.

PMID: 39748364 PMC: 11694429. DOI: 10.1186/s12943-024-02122-8.

The role of circular RNA targeting IGF2BPs in cancer-a potential target for cancer therapy.

Luo X, Shi J, Wang S, Jin X J Mol Med (Berl). 2024; 102(11):1297-1314.

PMID: 39287635 DOI: 10.1007/s00109-024-02488-8.

Poria acid inhibit the growth and metastasis of renal cell carcinoma by inhibiting the PI3K/akt/NF-κb signaling pathway.

Yang H, Zhao Y, Ren B, Wu Y, Qiu Z, Cheng Y Heliyon. 2024; 10(10):e31106.

PMID: 38779018 PMC: 11109894. DOI: 10.1016/j.heliyon.2024.e31106.

Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study.

Gatto F, Bratulic S, Jonasch E, Limeta A, Maccari F, Galeotti F JCO Precis Oncol. 2023; 7:e2200361.

PMID: 36848607 PMC: 10309541. DOI: 10.1200/PO.22.00361.

Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA.

Pan X, Huang B, Ma Q, Ren J, Liu Y, Wang C Clin Transl Med. 2022; 12(7):e994.

PMID: 35876041 PMC: 9309750. DOI: 10.1002/ctm2.994.

References

Luu V, Boysen G, Struckmann K, Casagrande S, von Teichman A, Wild P . Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res. 2009; 15(10):3297-304. DOI: 10.1158/1078-0432.CCR-08-2779. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Fuhrman S, Lasky L, Limas C . Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6(7):655-63. DOI: 10.1097/00000478-198210000-00007. View

Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A . Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010; 106(6):772-8. DOI: 10.1111/j.1464-410X.2010.09218.x. View

Trpkov K, Grignon D, Bonsib S, Amin M, Billis A, Lopez-Beltran A . Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013; 37(10):1505-17. DOI: 10.1097/PAS.0b013e31829a85d0. View

Bonsib S . T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol. 2005; 174(4 Pt 1):1199-202. DOI: 10.1097/01.ju.0000173631.01329.1f. View

Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F . Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 2009; 56(4):636-43. DOI: 10.1016/j.eururo.2009.06.036. View

Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R . Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012; 10:55. PMC: 3340316. DOI: 10.1186/1479-5876-10-55. View

Dahinden C, Ingold B, Wild P, Boysen G, Luu V, Montani M . Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res. 2009; 16(1):88-98. DOI: 10.1158/1078-0432.CCR-09-0260. View

10.

Srigley J, Delahunt B, Eble J, Egevad L, Epstein J, Grignon D . The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013; 37(10):1469-89. DOI: 10.1097/PAS.0b013e318299f2d1. View

11.

Morra L, Rechsteiner M, Casagrande S, Duc Luu V, Santimaria R, Diener P . Relevance of periostin splice variants in renal cell carcinoma. Am J Pathol. 2011; 179(3):1513-21. PMC: 3157167. DOI: 10.1016/j.ajpath.2011.05.035. View

12.

Genega E, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P . Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010; 134(6):873-9. PMC: 3778911. DOI: 10.1309/AJCPPPR57HNJMSLZ. View

13.

Argani P, Lae M, Hutchinson B, Reuter V, Collins M, Perentesis J . Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005; 29(2):230-40. DOI: 10.1097/01.pas.0000146007.54092.37. View

14.

Schraml P, Struckmann K, Bednar R, Fu W, Gasser T, Wilber K . CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol. 2001; 158(2):593-601. PMC: 1850295. DOI: 10.1016/s0002-9440(10)64001-1. View

15.

Bui M, Seligson D, Han K, Pantuck A, Dorey F, Huang Y . Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9(2):802-11. View

16.

Wu X, Weng L, Li X, Guo C, Pal S, Jin J . Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012; 7(5):e35661. PMC: 3356334. DOI: 10.1371/journal.pone.0035661. View

17.

Rechsteiner M, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H . VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res. 2011; 71(16):5500-11. DOI: 10.1158/0008-5472.CAN-11-0757. View

18.

Pena C, Lathia C, Shan M, Escudier B, Bukowski R . Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010; 16(19):4853-63. DOI: 10.1158/1078-0432.CCR-09-3343. View

19.

Delahunt B, Sika-Paotonu D, Bethwaite P, Jordan T, Magi-Galluzzi C, Zhou M . Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol. 2011; 35(8):1134-9. DOI: 10.1097/PAS.0b013e318220697f. View

20.

Argani P, Antonescu C, Illei P, Lui M, Timmons C, Newbury R . Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001; 159(1):179-92. PMC: 1850400. DOI: 10.1016/S0002-9440(10)61684-7. View